Evidence map›Paper›PMID 40978510›Full record

ArticleFrontiers in drug safety and regulation2025

Federated learning: a privacy-preserving approach to data-centric regulatory cooperation.

Alexander Horst, Paul Loustalot, Sanjeev Yoganathan, Ting Li, Joshua Xu, Weida Tong, David Schneider, Nicolas Löffler-Perez, Erminio Di Renzo, Michael Renaudin

Abstract read
In one paragraph

Article in Frontiers in drug safety and regulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alexander HorstSwissmedic 4.0 and Medical Device Vigilance, Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland.
Paul LoustalotQuinten Health, Paris, France.
Sanjeev YoganathanDivision of Medical Devices, The Danish Medicines Agency, Copenhagen, Denmark.
Ting LiNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, United States.
Joshua XuNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, United States.
Weida TongNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, United States.
David SchneiderSwissmedic 4.0 and Medical Device Vigilance, Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland.
Nicolas Löffler-PerezSwissmedic 4.0 and Medical Device Vigilance, Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland.
Erminio Di RenzoSwissmedic 4.0 and Medical Device Vigilance, Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland.
Michael RenaudinSwissmedic 4.0 and Medical Device Vigilance, Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory agencies aim to ensure the safety and efficacy of medical products but often face legal and privacy concerns that hinder collaboration at the data level. In this paper, we propose federated learning as an innovative method to enhance data-centric collaboration among regulatory agencies by enabling collaborative training of machine learning models without the need for direct data sharing, thereby preserving privacy and overcoming legal hurdles. We illustrate how Swissmedic, the Swiss Agency for Therapeutic Products, together with its partner agencies, proposes to use federated learning to improve TRICIA, an AI tool for assessing incoming reports of serious incidents related to medical devices. This approach enables the development of robust, generalisable risk assessment models that can potentially improve current processes. A proof of concept was deployed and thoroughly tested during the 14th Global Summit on Regulatory Science using synthetic data with participants from Swissmedic, the U.S. Food and Drug Administration (FDA), and the Danish Medicines Agency (DKMA), with promising initial results. This innovation has the potential to serve as a roadmap for other regulators to adopt similar approaches to optimize their own regulatory processes, contributing to a more integrated and efficient regulatory environment worldwide.

Indexed as

data privacyfederated learningmedical devicesregulatory sciencesrisk assessmentswissmedic

Identifiers

PMID40978510
PMCPMC12443094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.